Literature DB >> 21763494

Functional characterization of human cyclin T1 N-terminal region for human immunodeficiency virus-1 Tat transcriptional activation.

Kaori Asamitsu1, Yurina Hibi, Kenichi Imai, Ann Florence B Victoriano, Eiji Kurimoto, Koichi Kato, Takashi Okamoto.   

Abstract

Transcription of the human immunodeficiency virus type 1 (HIV-1) requires the interaction of the cyclin T1 (CycT1) subunit of a host cellular factor, positive transcription elongation factor b, with the viral Tat protein at the transactivation response (TAR) element of nascent viral transcripts. The involvement of the interaction between Tat and CycT1 is known to be through the Tat-TAR recognition motif (TRM) on CycT1. Here, we have further characterized this molecular interaction and clarified the role of the CycT1 N-terminal region in Tat action. We found crucial and distinctive roles of Q46, Q50 and F176 of human CycT1 protein in Tat-mediated transcription by creating various Ala substitution mutants of CycT1 based on its three-dimensional structure. We confirmed the involvement of these amino acid residues in binding to Tat with Q46 and Q50, and to a lesser extent with F176, by in vitro pull-down assay. Relative transactivation activities of wild-type CycT1 chimeras and mutant derivatives on the HIV-1 long terminal repeat were determined by luciferase reporter assays. Whereas CycT1 Q46A alone had impaired transcriptional activity, the CycT1(Q46A)-Tat chimeric protein retained almost full activity of the wild-type CycT1. However, CycT1 mutants (C261Y, Q50A or F176A) or their chimeric counterparts had lost the transactivation capacity. Moreover, a triple-mutant chimera containing Q46A, Q50A and F176A mutations completely abolished the transcriptional activity, indicating that these amino acid residues are involved through distinct mechanisms. These findings provide new insights for the development of anti-HIV drugs.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21763494     DOI: 10.1016/j.jmb.2011.04.061

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  6 in total

1.  Impact of Tat Genetic Variation on HIV-1 Disease.

Authors:  Luna Li; Satinder Dahiya; Sandhya Kortagere; Benjamas Aiamkitsumrit; David Cunningham; Vanessa Pirrone; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virol       Date:  2012-07-30

2.  A Cyclin T1 point mutation that abolishes positive transcription elongation factor (P-TEFb) binding to Hexim1 and HIV tat.

Authors:  Nina Verstraete; Alona Kuzmina; Gaelle Diribarne; Van Trung Nguyen; Lydia Kobbi; Monika Ludanyi; Ran Taube; Olivier Bensaude
Journal:  Retrovirology       Date:  2014-07-01       Impact factor: 4.602

3.  Molecular dynamics simulation and experimental verification of the interaction between cyclin T1 and HIV-1 Tat proteins.

Authors:  Kaori Asamitsu; Takatsugu Hirokawa; Yurina Hibi; Takashi Okamoto
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

4.  A single point mutation in cyclin T1 eliminates binding to Hexim1, Cdk9 and RNA but not to AFF4 and enforces repression of HIV transcription.

Authors:  Alona Kuzmina; Nina Verstraete; Sigal Galker; Maayan Maatook; Olivier Bensaude; Ran Taube
Journal:  Retrovirology       Date:  2014-07-01       Impact factor: 4.602

5.  MD simulation of the Tat/Cyclin T1/CDK9 complex revealing the hidden catalytic cavity within the CDK9 molecule upon Tat binding.

Authors:  Kaori Asamitsu; Takatsugu Hirokawa; Takashi Okamoto
Journal:  PLoS One       Date:  2017-02-08       Impact factor: 3.240

Review 6.  HIV Tat/P-TEFb Interaction: A Potential Target for Novel Anti-HIV Therapies.

Authors:  Kaori Asamitsu; Koh Fujinaga; Takashi Okamoto
Journal:  Molecules       Date:  2018-04-17       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.